article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.

AFIB 59
article thumbnail

Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC

DAIC

Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.

AFIB 52
article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.

AFIB 52
article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1 1 These included one pseudoaneurysm, one PV stenosis and one hematoma.1

Ablation 105
article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

"Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. In the U.S.,